Companies Dominating the Small Interfering RNA Landscape
- GE
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Thermo Scientific
- Arbutus Biopharma
- Sanofi Genzyme
- Sylentis
- Arrowhead Research
- Genecon Biotechnologies
- Silent Therapeutics
- Horizon Discovery
- OPKO Health
- Agios Pharmaceuticals, Inc.
- Novartis
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of small interfering RNA is estimated at USD 17.03 billion.
The small interfering RNA market size was valued at USD 14.97 billion in 2024 and is likely to cross USD 117.84 billion by 2037, expanding at more than 17.2% CAGR during the forecast period i.e., between 2025-2037. Rising cases of cancer across the globe and the growing partnerships and collaborations will drive the market growth.
North America industry is likely to account for largest revenue share of 37% by 2037, impelled by increasing spending in healthcare in the region.
The major players in the market include GE, Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, Agios Pharmaceuticals, Inc., Novartis
